Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 540

1.

Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction.

Weill D, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, Kirklin JK, McGiffin DC.

Am J Transplant. 2003 Apr;3(4):492-6.

2.

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.

Dunn DL, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HH Jr, Gores PF, Gruessner RW, Matas AJ, Payne WD, et al.

Transplantation. 1994 Mar 27;57(6):876-84.

PMID:
8154035
3.

Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.

Valentine VG, Weill D, Gupta MR, Raper B, Laplace SG, Lombard GA, Bonvillain RW, Taylor DE, Dhillon GS.

J Heart Lung Transplant. 2008 Aug;27(8):875-81. doi: 10.1016/j.healun.2008.05.009. Epub 2008 Jun 30.

PMID:
18656801
4.

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.

Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV.

Transplantation. 1997 Jul 15;64(1):66-73.

PMID:
9233703
5.

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.

Transplantation. 1998 Dec 27;66(12):1682-8.

PMID:
9884259
6.

Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.

Ruttmann E, Geltner C, Bucher B, Ulmer H, Höfer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Müller LC.

Transplantation. 2006 May 27;81(10):1415-20.

PMID:
16732179
7.

Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.

Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L; Euro-SPK Study Group..

Nephrol Dial Transplant. 2005 May;20 Suppl 2:ii25-ii32, ii62.

PMID:
15814546
8.

[The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].

Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.

Dtsch Med Wochenschr. 1997 May 2;122(18):565-71. German.

PMID:
9190308
9.
10.
11.

Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.

Bonaros NE, Kocher A, Dunkler D, Grimm M, Zuckermann A, Ankersmit J, Ehrlich M, Wolner E, Laufer G.

Transplantation. 2004 Mar 27;77(6):890-7.

PMID:
15077033
12.

Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.

Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.

Transpl Infect Dis. 2000 Sep;2(3):112-7.

PMID:
11429021
13.

Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.

Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R.

Clin Transplant. 2004 Apr;18(2):179-85.

PMID:
15016133
14.

Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.

Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP.

J Heart Lung Transplant. 2003 Jul;22(7):754-63.

PMID:
12873543
15.

Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.

Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A.

Transplantation. 1999 Jan 27;67(2):315-20.

PMID:
10075601
16.

Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.

Thomas LD, Milstone AP, Miller GG, Loyd JE, Stephen Dummer J.

Clin Transplant. 2009 Aug-Sep;23(4):476-83. doi: 10.1111/j.1399-0012.2009.00990.x. Epub 2009 May 4.

PMID:
19453645
17.

Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.

Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.

Transplant Proc. 2004 Jul-Aug;36(6):1847-9.

PMID:
15350495
18.

Prophylaxis of cytomegalovirus disease in mismatched patients after heart transplantation using combined antiviral and immunoglobulin therapy.

Czer LS, Ruzza A, Vespignani R, Rafiei M, Pixton JR, Awad M, De Robertis M, Wong AV, Trento A.

Transplant Proc. 2011 Jun;43(5):1887-92. doi: 10.1016/j.transproceed.2011.01.189.

PMID:
21693295
20.

Supplemental Content

Support Center